Dr. Alexander Drilon, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Non-Small Cell Lung Cancer
Studies Solid Tumors
11 reported clinical trials
13 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
RET positive
Stage IV
Stage III
2Solid Tumors
Stage IV
Stage III
ALK positive
Affiliated Hospitals
Clinical Trials Alexander Drilon, MD is currently running
Selpercatinib
for Non-Small Cell Lung Cancer
This trial is testing if the drug selpercatinib can safely and effectively prevent lung cancer from returning in patients who have had treatment. It focuses on people with early-stage lung cancer. The drug works by blocking proteins that help cancer cells grow.
Recruiting1 award Phase 38 criteria
Lorlatinib + Ramucirumab
for Lung Cancer
This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.
Recruiting1 award Phase 1 & 213 criteria
More about Alexander Drilon, MD
Clinical Trial Related3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Alexander Drilon, MD has experience with
- Cabozantinib
- Repotrectinib (TPX-0005)
- LOXO-292
- Placebo
- Selpercatinib
- Selpercatinib (LOXO-292)
Breakdown of trials Alexander Drilon, MD has run
Non-Small Cell Lung Cancer
Solid Tumors
Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander Drilon, MD specialize in?
Alexander Drilon, MD focuses on Non-Small Cell Lung Cancer and Solid Tumors. In particular, much of their work with Non-Small Cell Lung Cancer has involved RET positive patients, or patients who are Stage IV.
Is Alexander Drilon, MD currently recruiting for clinical trials?
Yes, Alexander Drilon, MD is currently recruiting for 6 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Alexander Drilon, MD has studied deeply?
Yes, Alexander Drilon, MD has studied treatments such as Cabozantinib, Repotrectinib (TPX-0005), LOXO-292.
What is the best way to schedule an appointment with Alexander Drilon, MD?
Apply for one of the trials that Alexander Drilon, MD is conducting.
What is the office address of Alexander Drilon, MD?
The office of Alexander Drilon, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.